Kintara Therapeutics Inc.
13F holders, Q3 2024 (September 30)14holders −3
3new positions
6sold out
$0.19avg. 13F price*
At the end of Q3 2024, 14 institutions reported holding Kintara Therapeutics Inc. in their 13F filings, down 3 from Q2 2024. 3 opened new positions and 6 sold out. The largest holders were Geode Capital Management, LLC ($87K), Susquehanna International Group, LLP ($25K) and UBS Group AG ($20K).
- Company
- Kintara Therapeutics Inc.
- CUSIP
- 49720K200
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $16K |
| Exits | 6 | $52K |
All 13F filers, Q2 2024 → Q3 2024: 236,854 shares bought and 220,719 shares sold, net +16,135 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Geode Capital Management, LLC | 0.00% | Add +29.2% | 444,417 | $87K |
| Susquehanna International Group, LLP | 0.00% | Add +16.9% | 127,698 | $25K |
| UBS Group AG | 0.00% | Add +36.9% | 103,771 | $20K |
| Nantahala Capital Management, LLC | 0.00% | New | 79,766 | $16K |
| Clear Creek Financial Management, LLC | 0.00% | No change | 27,500 | $5K |
| Vanguard Group Inc. | 0.00% | No change | 12,455 | $2K |
| Baader Bank Aktiengesellschaft | 0.00% | Reduce -64.6% | 15,116 | $2K |
| State Street Corp. | 0.00% | No change | 10,721 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +468.9% | 9,859 | $2K |
| Wells Fargo & Company | 0.00% | New | 1,615 | $315 |
| Osaic Holdings, Inc. | 0.00% | No change | 1,029 | $205 |
| Bank of America Corp. | 0.00% | Reduce -80.0% | 454 | $89 |
| Morgan Stanley | 0.00% | New | 450 | $88 |
| Acadian Asset Management LLC | 0.00% | No change | 350 | $0 |
"% of holder's portfolio" is KINTARA THERAPEUTICS INC's weight in each manager's 13F, not the share of Kintara Therapeutics Inc. the manager owns.